Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Company's marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The Company's product candidates in Phase III include Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis. The Company's product candidates in Phase II include BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The Company's product candidates in Phase I include IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

The Company markets ENBREL primarily in the United States. ENBREL is used primarily in the indications for the treatment of adult patients with various conditions, such as moderately to severely active rheumatoid arthritis, chronic moderate-to-severe plaque psoriasis patients, and active psoriatic arthritis. The Company markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count. It markets Aranesp primarily in Europe and in the United States. Aranesp is indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both patients on dialysis and patients not on dialysis. Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in patients with non-myeloid malignancies. It markets EPOGEN in the United States for dialysis patients. EPOGEN is indicated to treat anemia caused by CKD in patients on dialysis to lessen the need for red blood cell transfusions.

The Company markets cinacalcet as Sensipar primarily in the United States and as Mimpara primarily in Europe. Cinacalcet is used primarily in the indication for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with CKD on dialysis. The Company markets XGEVA primarily in the United States and Europe. XGEVA is used primarily in the indication for the prevention of skeletal-related events (SREs), such as pathological fracture, radiation to bone, spinal cord compression or surgery to bone, in patients with bone metastases from solid tumors. It markets Prolia primarily in the United States and Europe. In the United States, Prolia is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients having failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. It markets NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), primarily in the United States, Canada and Europe. NEUPOGEN is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count.

The Company competes with Johnson & Johnson, Merck & Company, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Galenica Group, F. Hoffmann-La Roche Ltd., Novartis, Takeda Pharmaceutical Company Limited, Celgene Corporation, Sanofi and Regeneron Pharmaceuticals, Inc.

1 Amgen Center Dr

The company trades on NASDAQ exchange. The company headquarter is located in Thousand Oaks, California. The company was established in the 1980.

TickerAMGN
Long NameAmgen Inc
Short NameAmgen